Study: Retatrutide decreases AHI in adults with sleep apnea
By HME News Staff
Updated 10:31 AM CDT, Thu October 22, 2026
BOSTON – Retatrutide, an investigational triple agonist of glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1 and glucagon receptors, may be useful for treating obstructive sleep apnea (OSA), according to a study published in the New England Journal of Medicine. “In adults with OSA and obesity or overweight with or without Type 2 diabetes, retatrutide resulted in significantly greater decreases in the AHI than placebo,” researchers concluded. A total of 243 participants underwent randomization in TRIUMPH-1-OSA and 448 in TRIUMPH-2-OSA. The baseline mean AHI was 58.6 and 55.9 events per hour, respectively, and the mean body weight was 119.6 and 115.9 kg. At 80 weeks, the mean changes in the AHI (hybrid-treatment estimand) with retatrutide in TRIUMPH-1-OSA were −22.9 (4 mg), −34.3 (9 mg), and −31.7 (12 mg) events per hour, versus −9.9 with placebo (difference vs. placebo, −13.0 [95% confidence interval {CI}, −23.0 to −3.0], −24.4 [95% CI, −34.1 to −14.7], and −21.9 [95% CI, −32.2 to −11.5], respectively). Read more about the methods and results here.
Comments